William Schaffner, MD, medical director at the National Foundation for Infectious Diseases (NFID), and Patsy Stinchfield, RN, MS, CPNP, president-elect of NFID, explain how the COVID-19 pandemic has had an impact on the seasonality of respiratory syncytial virus (RSV).
William Schaffner, MD, medical director at the National Foundation for Infectious Diseases (NFID), and Patsy Stinchfield, RN, MS, CPNP, president-elect of NFID, explain how the COVID-19 pandemic has had an impact on the seasonality of respiratory syncytial virus (RSV).
Transcript
How has the COVID-19 pandemic impacted the normal seasonality of respiratory syncytial virus?
Stinchfield: The COVID-19 pandemic has disrupted a lot of things, including other viruses, some of which have had to take a backseat to this virus. RSV season, as we typically see it in the fall and winter, was definitely disrupted. At the beginning of the pandemic, we saw some coinfections in children—both RSV and SARS-CoV-2, or influenza [and] SARS-CoV-2, a little bit of influenza and RSV. The second winter, though, we really didn't see much RSV and then, very strangely, RSV reemerged in the summer unexpectedly and with a vengeance. The pediatric population has quieted down, and now when it's supposed to be high right now, it's really not as much of a factor.
Schaffner: And that's been true largely across the country, because it's happened exactly as Patsy's described in Minnesota [and] that's exactly what's happened here in Tennessee. RSV has come early, disappeared early, or almost disappeared early. We're looking forward to reviewing our data to see how many coinfections we will find of both RSV and COVID at the same time. How frequent is it? Can we distinguish these patients from others? Do they produce more severe disease when they are present at the same time? Those are questions that are still unanswered.
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment
April 4th 2025Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.
Read More
Bridging Education Gaps in Treatment for Scarring Alopecia With Innovative Approaches
March 28th 2025Crystal Aguh, MD, FAAD, Johns Hopkins School of Medicine faculty, highlights the critical need for comprehensive education on hair loss across diverse hair types, stressing the importance of understanding inflammatory pathways for developing targeted therapies.
Read More